Droxidopa in neurogenic orthostatic hypotension

References

• FDA. Definition of orphan disease and orphan products. (editors) 2012
   Google Scholar
• Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011;21(2):69-72
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Holmes CS, Dendi R, et al. Orthostatic hypotension from sympathetic denervation in Parkinson’s disease. Neurology 2002;58(8):1247-55
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Biaggioni I. Autonomic failure in neurodegenerative disorders. Semin Neurol 2003;23(4):351-63
   Google Scholar
• Freeman R. Clinical practice Neurogenic orthostatic hypotension. N Engl J Med 2008;358(6):615-24
   PubMed Web of Science ®Google Scholar
• Masaki KH, Schatz IJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation 1998;98(21):2290-5
   PubMed Web of Science ®Google Scholar
• Berganzo K, Diez-Arrola B, Tijero B, et al. Nocturnal hypertension and dysautonomia in patients with Parkinson’s disease: are they related? J Neurol 2013;260(7):1752-6
   PubMed Web of Science ®Google Scholar
• Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord 2015
   Google Scholar
• Kaufmann H. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res 1996;6(2):125-6
   PubMed Web of Science ®Google Scholar
• Horowitz DR, Kaufmann H. Autoregulatory cerebral vasodilation occurs during orthostatic hypotension in patients with primary autonomic failure. Clin Auton Res 2001;11(6):363-7
   PubMed Web of Science ®Google Scholar
• Arnold AC, Biaggioni I. Management approaches to hypertension in autonomic failure. Curr Opin Nephrol Hypertens 2012;21(5):481-5
   PubMed Web of Science ®Google Scholar
• . Dopamine Beta-Hydroxylase Deficiency. In: GeneReviews(R). Robertson D, Garland EMPagon RA, et al. Eds. (Seattle (WA) 1993
   Google Scholar
• Norcliffe-Kaufmann L, Axelrod F, Kaufmann H. Afferent baroreflex failure in familial dysautonomia. Neurology 2010;75(21):1904-11
   Google Scholar
• Palma JA, Carmona-Abellan MM, Barriobero N, et al. Is cardiac function impaired in premotor Parkinson’s disease? A retrospective cohort study. Mov Disord 2013;28(5):591-6
   Google Scholar
• Norcliffe-Kaufmann L, Kaufmann H. Is ambulatory blood pressure monitoring useful in patients with chronic autonomic failure? Clin Auton Res 2014;24(4):189-92
   Google Scholar
• Ejaz AA, Kazory A, Heinig ME. 24-hour blood pressure monitoring in the evaluation of supine hypertension and orthostatic hypotension. J Clin Hypertens (Greenwich) 2007;9(12):952-5
   PubMedGoogle Scholar
• Shibao C, Lipsitz LA, Biaggioni I. ASH position paper: evaluation and treatment of orthostatic hypotension. J Clin Hypertens (Greenwich) 2013;15(3):147-53
   PubMed Web of Science ®Google Scholar
• Schroeder C, Jordan J, Kaufmann H. Management of neurogenic orthostatic hypotension in patients with autonomic failure. Drugs 2013;73(12):1267-79
   Google Scholar
• Perera R, Isola L, Kaufmann H. Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res 1995;5(4):211-13
   PubMed Web of Science ®Google Scholar
• Weinberg AD, Minaker KL. Dehydration. Evaluation and management in older adults. council on scientific affairs, American Medical Association. JAMA 1995;274(19):1552-6
   PubMed Web of Science ®Google Scholar
• Krediet CT, van Lieshout JJ, Bogert LW, et al. Leg crossing improves orthostatic tolerance in healthy subjects: a placebo-controlled crossover study. Am J Physiol Heart Circ Physiol 2006;291(4):H1768-72
   Google Scholar
• Wieling W, van Lieshout JJ, van Leeuwen AM. Physical manoeuvres that reduce postural hypotension in autonomic failure. Clin Auton Res 1993;3(1):57-65
   Google Scholar
• May M, Jordan J. The osmopressor response to water drinking. Am J Physiol Regul Integr Comp Physiol 2011;300(1):R40-6
   Google Scholar
• McHugh J, Keller NR, Appalsamy M, et al. Portal osmopressor mechanism linked to transient receptor potential vanilloid 4 and blood pressure control. Hypertension 2010;55(6):1438-43
   PubMed Web of Science ®Google Scholar
• MacLean AR, Allen EV. Orthostatic hypotension and orthostatic tachycardia - Treatment with the “head-up” bed. J Am Med Assoc 1940;115:2162-7
   Google Scholar
• Diedrich A, Biaggioni I. Segmental orthostatic fluid shifts. Clin Auton Res 2004;14(3):146-7
   Google Scholar
• Smit AA, Wieling W, Fujimura J, et al. Use of lower abdominal compression to combat orthostatic hypotension in patients with autonomic dysfunction. Clin Auton Res 2004;14(3):167-75
   PubMed Web of Science ®Google Scholar
• Kooner JS, Raimbach S, Watson L, et al. Relationship between splanchnic vasodilation and postprandial hypotension in patients with primary autonomic failure. J Hypertens Suppl 1989;7(6):S40-1
   Google Scholar
• Berne C, Fagius J, Niklasson F. Sympathetic response to oral carbohydrate administration. Evidence from microelectrode nerve recordings. J Clin Invest 1989;84(5):1403-9
   Google Scholar
• Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Intern Med 1995;122(4):286-95
   Google Scholar
• Chobanian AV, Volicer L, Tifft CP, et al. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med 1979;301(2):68-73
   PubMed Web of Science ®Google Scholar
• Norcliffe-Kaufmann L, Axelrod FB, Kaufmann H. Developmental abnormalities, blood pressure variability and renal disease in Riley Day syndrome. J Hum Hypertens 2013;27(1):51-5
   Google Scholar
• Kaufmann H, Brannan T, Krakoff L, et al. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 1988;38(6):951-6
   Google Scholar
• Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998;51(1):120-4
   PubMed Web of Science ®Google Scholar
• Ramirez CE, Okamoto LE, Arnold AC, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 2014;64(6):1235-40
   PubMed Web of Science ®Google Scholar
• Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63(4):513-18
   Google Scholar
• Jordan J, Shannon JR, Biaggioni I, et al. Contrasting actions of pressor agents in severe autonomic failure. Am J Med 1998;105(2):116-24
   PubMed Web of Science ®Google Scholar
• Hoeldtke RD, Israel BC. Treatment of orthostatic hypotension with octreotide. J Clin Endocrinol Metab 1989;68(6):1051-9
   Google Scholar
• Ooi WL, Hossain M, Lipsitz LA. The association between orthostatic hypotension and recurrent falls in nursing home residents. Am J Med 2000;108(2):106-11
   PubMed Web of Science ®Google Scholar
• Rosenmund KW, Dornsaft H. Über Oxy- und Hioxyphenylserin und die Muttersubstanz des Adrenalins. Ber Dtsch Chem Ges 1919;52:1734-49
   Google Scholar
• Blaschko H, Holton P, Stanley GH. The decarboxylation of -3: 4-dihydroxyphenylserine (noradrenaline carboxylic acid). Br J Pharmacol Chemother 1948;3(4):315-19
   PubMed Web of Science ®Google Scholar
• Beyer KH, Blaschko H, Burn JH, Langemann H. Enzymic formation of noradrenaline in mammalian tissue extracts. Nature 1950;165(4206):926
   PubMed Web of Science ®Google Scholar
• Blaschko H, Burn JH, Langemann H. The formation of noradrenaline from dihydroxyphenylserine. Br J Pharmacol Chemother 1950;5(3):431-7
   PubMed Web of Science ®Google Scholar
• Schmiterlow CG. The formation in vivo of noradrenaline from 3:4-dihydroxyphenylserine (noradrenaline carboxylic acid). Br J Pharmacol Chemother 1951;6(1):127-34
   Google Scholar
• Araki H, Tanaka C, Fujiwara H, et al. Pressor effect of L-threo-3,4-dihydroxyphenylserine in rats. J Pharm Pharmacol 1981;33(12):772-7
   PubMed Web of Science ®Google Scholar
• Suzuki T, Higa S, Sakoda S, et al. Orthostatic hypotension in familial amyloid polyneuropathy: treatment with DL-threo-3,4-dihydroxyphenylserine. Neurology 1981;31(10):1323-6
   PubMed Web of Science ®Google Scholar
• Biaggioni I, Robertson D. Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency. Lancet 1987;2(8569):1170-2
   PubMed Web of Science ®Google Scholar
• Man in ’t Veld AJ, Boomsma F, van den Meiracker AH, Schalekamp MA. Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency. Lancet 1987;2(8569):1172-5
   Google Scholar
• Birkmayer W, Birkmayer G, Lechner H, Riederer P. DL-3,4-threo-DOPS in Parkinson’s disease: effects on orthostatic hypotension and dizziness. J Neural Transm 1983;58(3-4):305-13
   Google Scholar
• Sakoda S, Suzuki T, Higa S, et al. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report. Eur Neurol 1985;24(5):330-4
   PubMed Web of Science ®Google Scholar
• Senda Y, Muto T, Matsuoka Y, et al. [Clinical effects of oral L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in patients with Shy-Drager syndrome]. Rinsho Shinkeigaku 1987;27(3):300-4
   Google Scholar
• Kachi T, Iwase S, Mano T, et al. Effect of L-threo-3,4-dihydroxyphenylserine on muscle sympathetic nerve activities in Shy-Drager syndrome. Neurology 1988;38(7):1091-4
   PubMed Web of Science ®Google Scholar
• Iida N, Tsubakihara Y, Shirai D, et al. Treatment of dialysis-induced hypotension with L-threo-3,4-dihydroxyphenylserine. Nephrol Dial Transplant 1994;9(8):1130-5
   PubMed Web of Science ®Google Scholar
• Bartholini J, Constantinidis J, Puig M, et al. The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine. J Pharmacol Exp Ther 1975;193(2):523-32
   Google Scholar
• Inagaki C, Fujiwara H, Tanaka C. Inhibitory effect of (+)threo-3,4-dihydroxy-phenylserine (DOPS) on decarboxylation of (-)threo-dops. Jpn J Pharmacol 1976;26(3):380-2
   PubMedGoogle Scholar
• Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014;83(4):328-35
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003;108(6):724-8
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Holmes C, Kaufmann H, Freeman R. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res 2004;14(6):363-8
   PubMed Web of Science ®Google Scholar
• Goldstein DS. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev 2006;24(3-4):189-203
   PubMedGoogle Scholar
• Ishikawa Y, Kato Y, Murakami Y, et al. Effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS) on catecholamine levels in plasma and cerebrospinal fluid (CSF) in anesthetized rats. Proc Soc Exp Biol Med 1987;184(2):197-200
   Google Scholar
• Tohgi H, Abe T, Takahashi S. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J Neural Transm Park Dis Dement Sect 1993;5(1):27-34
   PubMedGoogle Scholar
• Tohgi H, Abe T, Takahashi S, et al. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients. Neurosci Lett 1990;116(1-2):194-7
   Google Scholar
• Hoeldtke RD, Cilmi KM, Mattis-Graves K. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension. Clin Pharmacol Ther 1984;36(3):302-6
   PubMed Web of Science ®Google Scholar
• Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology 1999;53(9):2151-7
   Google Scholar
• Kaufmann H, Oribe E, Yahr MD. Differential effect of L-threo-3,4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure. J Neural Transm Park Dis Dement Sect 1991;3(2):143-8
   PubMedGoogle Scholar
• Mathias CJ, Senard JM, Braune S, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 2001;11(4):235-42
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Malamut R, Norcliffe-Kaufmann L, et al. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res 2012;22(2):79-90
   PubMed Web of Science ®Google Scholar
• Biaggioni I, Freeman R, Mathias CJ, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension 2015;65(1):101-7
   Google Scholar
• Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the Short-Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson’s Disease (nOH306B). Mov Disord 2014
   Google Scholar
• Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A). J Parkinsons Dis 2014;4(1):57-65
   PubMedGoogle Scholar
• Yamamoto K, Morita S, Ikeda S, Yanagisawa N. [Hyperthermia in a Shy-Drager syndrome patient–pathophysiological effects of body temperature and L-DOPS on orthostatic hypotension]. Rinsho Shinkeigaku 1993;33(1):68-73
   Google Scholar
• Ueda M, Hamamoto M, Otsubo K, et al. [Monoamine imbalance of the central nervous system in a case of Shy-Drager syndrome with recurrent attacks of a neuroleptic malignant syndrome]. Rinsho Shinkeigaku 1996;36(5):696-8
   Google Scholar
• Yoshikawa H, Oda Y, Sakajiri K, et al. Pure akinesia manifested neuroleptic malignant syndrome: a clinical variant of progressive supranuclear palsy. Acta Neuropathol 1997;93(3):306-9
   Google Scholar
• Tanaka H, Yamaguchi H, Mino M. The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance. Clin Auton Res 1996;6(4):189-93
   Google Scholar
• Kaufmann H. Could treatment with DOPS do for autonomic failure what DOPA did for Parkinson’s disease? Neurology 1996;47(6):1370-1
   Google Scholar
• Yoshikawa H, Kawai K, Inoue S, et al. [A case of diabetic orthostatic hypotension effectively managed with L-dops (L-threo-3,4-dihydroxyphenylserine)]. Nihon Naika Gakkai Zasshi 1987;76(11):1695-700
   Google Scholar
• Wecht JM, Rosado-Rivera D, Weir JP, et al. Hemodynamic effects of L-threo-3,4-dihydroxyphenylserine (Droxidopa) in hypotensive individuals with spinal cord injury. Arch Phys Med Rehabil 2013;94(10):2006-12
   Google Scholar
• Muneta S, Iwata T, Hiwada K, et al. Effect of L-threo-3, 4-dihydroxyphenylserine on orthostatic hypotension in a patient with spinal cord injury. Jpn Circ J 1992;56(3):243-7
   Google Scholar
• Akizawa T, Koshikawa S, Iida N, et al. Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients. Nephron 2002;90(4):384-90
   Google Scholar
• Freeman R, Young J, Landsberg L, Lipsitz L. The treatment of postprandial hypotension in autonomic failure with 3,4-DL-threo-dihydroxyphenylserine. Neurology 1996;47(6):1414-20
   PubMed Web of Science ®Google Scholar